Metagenomi (MGX) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - Metagenomi reported a quarterly loss of $0.55 per share, which was better than the Zacks Consensus Estimate of a loss of $0.60, representing an earnings surprise of +8.33% [1] - The company generated revenues of $8.66 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 6.44% and down from $11.51 million a year ago [2] - Metagenomi shares have declined approximately 40.4% year-to-date, contrasting with the S&P 500's gain of 16.2% [3] Financial Performance - Over the last four quarters, Metagenomi has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $9.26 million, and for the current fiscal year, it is -$2.39 on revenues of $30.44 million [7] Market Outlook - The sustainability of Metagenomi's stock price movement will largely depend on management's commentary during the earnings call [3] - The Zacks Rank for Metagenomi is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] - The Medical - Drugs industry, to which Metagenomi belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]